PD-1 inhibitor sintilimab treated patients with metastatic triple-negative breast cancer.

Patients with primary TNBC, compared to those with other subtypes of primary tumors, gained an obvious trend of efficacy benefit; however, the statistical difference was not reached ( p > 0.05, Figure 2D ).

also in 250 other papers